BI sees 1H growth, oncology promise, but Spiriva gap looms
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim saw its prescription medicines business rise 3.5% over the first half of 2013, with COPD product Spiriva (tiotropium) still topping the list as the company's best-selling product. But with the drug due to come off patent in 2016 and nothing coming through the company's respiratory pipeline to fill the revenue gap, analysts do not anticipate that the growth spurt will last, despite the company's flourishing oncology presence.